Didier Surdez

Medicine · Health Sciences

35h-index7.8kcitations235works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(87), Neuroblastoma Research and Treatments(67), Cancer, Hypoxia, and Metabolism(31), Cancer Genomics and Diagnostics(31), Lymphoma Diagnosis and Treatment(28)

Publications235 total

HIF1α gates tendon response to overload and drives tendinopathy independently of vascular recruitment
Science Translational Medicine·2026
Supplemental Table 1 from Advancing Preclinical Biology for Ewing Sarcoma: An International Effort
2026Open Access
Data from Advancing Preclinical Biology for Ewing Sarcoma: An International Effort
2026Open Access
The hegemonic EWSR1::ETS oncoprotein overrules core regulatory circuitry principles in Ewing sarcoma
npj Precision Oncology·2025Open Access
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition
2025Open Access
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial
British Journal of Cancer·2025Open Access
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
JCO Precision Oncology·2025
Advancing Preclinical Biology for Ewing Sarcoma: An International Effort
Molecular Cancer Therapeutics·2025· 1 citedOpen Access
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
Nature Communications·2025· 2 citedOpen Access
Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis
EMBO Reports·2025Open Access
Targeting metastasis in paediatric bone sarcomas
Molecular Cancer·2025· 9 citedOpen Access
Abstract 1304: A novel organoid-based model to study pediatric tumor metastasis to the lung
Cancer Research·2025
Abstract 3942: 3D models reveal novel drug synergies and mevalonate pathway activation in Ewing sarcoma
Cancer Research·2025
page 1 of 12Next →

Frequent Co-authors

Olivier Delattre(46), Sakina Zaïdi(17), Gaëlle Pierron(15), Thomas G. P. Grünewald(13), Franck Tirode(12), Sylvain Baulande(12), Sandrine Grossetête(10), Eve Lapouble(8), Virginie Raynal(8), Isabelle Janoueix‐Lerosey(8), Gudrun Schleiermacher(7), Florencia Cidre‐Aranaz(6), Heinrich Kovar(6), Uta Dirksen(6), Valentina Boeva(6), Cécile Pierre‐Eugène(6), Birgit Geoerger(6), Franck Bourdeaut(6), Olivier Mirabeau(6), Zhi‐Yan Han(6)